PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement • June 1st, 2021
Administrative information: Universal trial number: U1111-1201-6256 EudraCT number: 2017-003619-20 Version: 3.0 US Final Official name of the study:Long-term effects of semaglutide on diabetic retinopathy in patients with type 2 diabetes (FOCUS) Research sponsor contact information: Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required byU.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk- trials.com, www.clinicaltrialsregister.eu and potentially in other regional or local registries
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement • April 12th, 2021
Universal trial number: U1111-1247-0210 EudraCT number: 2020-000299-39 Version: Final 3.0_US Official name of the study: Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes Research sponsor contact information: Novo Nordisk Inc, 800 Scudders Mill Road, Plainsboro, NJ 08536 A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk-trials.com, www.clinicaltrialsregister.eu and potentially in other regional or local registries.
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement • December 24th, 2020
TITLE: A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti- diabetic treatment, in insulin naïve subjects with type 2 diabetes.
PARTICIPANT INFORMATION AND AGREEMENT TO TAKE PART FORMParticipant Information and Agreement • October 7th, 2019
Administrative information: Universal trial number: U1111-1218-5368 EudraCT number/IND number: 2018-003141-42 Version: US_6.0 Official name of the study: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL) Research sponsor contact information: Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required byU.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time. Information about the study and the results will also be made available at www.novonordisk- trials.com and www.clinicaltrialsregister.eu.
Discovery Southeast Participant Information and AgreementParticipant Information and Agreement • February 18th, 2020
This form is for the parent or legal guardian to complete, unless the participant is 18 or older, in which case the participant should complete it.
